Infinity Pharmaceuticals, Inc.(INFI)

Description: Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Its lead product candidates include IPI-145 and IPI-443, inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K); Retaspimycin HCl, a heat shock protein 90 inhibitor; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company is pursuing a dual development path for IPI-145 in both hematologic malignancies and inflammation. IPI-145 is in an ongoing Phase I dose-escalation trial in patients with advanced hematologic malignancies and in a Phase IIa study in patients with mild, allergic asthma. In addition, the company plans to initiate a Phase II signal-finding study in patients with rheumatoid arthritis. IPI-443 is undergoing preclinical studies to enable Phase I development. Retaspimycin HCl is in a Phase II trial in combination with docetaxel to treat patients with non-small cell lung cancer (NSCLC) and in an exploratory Phase Ib/II trial in combination with everolimus in NSCLC patients with a KRAS mutation. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

---

Keywords: Chemical Substances Disease Drug Discovery Inflammation Acid Rheumatoid Arthritis Asthma Non Small Cell Lung Cancer Small Cell Lung Cancer Fatty Acids Hematologic Malignancies Nsclc Kras Docetaxel Phosphoinositide 3 Kinase Inhibitor Purines Pyrimidines Allergic Asthma

---

Home Page: www.infi.com

INFI Technical Analysis

1100 Massachusetts Avenue
Cambridge, MA 02138
United States
Phone: 617 453 1000

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)